|D007945||Leukemia, Lymphoid NIH||1.00|
|D015451||Leukemia, Lymphocytic, Chronic, B-Cell NIH||1.00|
There is one clinical trial.
The COVID-19 epidemic (Coronavirus Disease 2019) which is currently raging in France is an emerging infectious disease linked to a virus of the genus coronavirus (SARS-CoV-2). The first cases were reported in Wuhan, China, in late December 2019 . Globally, it has been placed in the "pandemic" stage by the WHO since March 11, 2020. Coronavirus viruses have been responsible for epidemics in the past such as the SARS epidemic in 2002 (Syndrome Severe Acute Respiratory) linked to the SARS-CoV virus, or the epidemic of MERS (Middle East Respiratory Syndrome) that affected the Middle East in 2012. Patients with chronic lymphocytic leukemia (CLL) / lymphocytic lymphoma or Waldenstrom Disease (WD) therefore represent a population at high risk of developing a severe form in the event of COVID-19 infection. To date, no data is available in the literature to assess the impact of the COVID-19 epidemic in this population of patients with CLL / lymphocytic lymphoma or WD.
Description: Hematological pathology DescriptionMeasure: Prognostic factors for healing of COVID-19 infection Time: Day 0
Description: Describe the management carried out concerning Coronavirus infection and its impact on the treatment of hemopathy.Measure: Medical care of Coronavirus infection Time: within 12 months after diagnosis
Description: Allow national epidemiological monitoring and regularly inform the hematology community.Measure: national epidemiological monitoring Time: through study completion, an average of 2 years